Effectiveness of hepatitis B vaccination in children of chronic hepatitis B mothers

Saudi Medical Journal

Volumn 25, Issue 10, 2004, Pages 1414-1418

  Adibi, Peyman ^a,e   Ghassemian, Rezvan ^b   Alavian, Seyed Moayed ^c   Ranjbar, Mitra ^b   Mohammadalizadeh, Amir H ^b   Nematizadeh, Fariborz ^c   Mamani, Mojgan ^d   Rezazadeh, Mahdi ^d   Keramat, Fariba ^d   Ardalan, Ali ^b   Esmaeile, Abbas ^b   Zali, Mohammad R ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Sina Hospital Hamedan   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; IRAN; MAJOR CLINICAL STUDY; PLACENTAL TRANSFER; PRENATAL CARE; PRENATAL SCREENING; RISK ASSESSMENT; VIRUS IMMUNITY; VIRUS TRANSMISSION;

AGE DISTRIBUTION; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INFANT; INFANT, NEWBORN; IRAN; MALE; MONTE CARLO METHOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; PRIMARY PREVENTION; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; VACCINATION;

EID: 7244248867     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Maynard JE, Hepatitis B: global importance and need for control. Vaccine 1990; 8 (Suppl); 18-20.
2. Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population a viral marker study. Ann Acad Med Singapore 1980; 9: 144-148.
3. Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and Iran. J Irn Med Council 1997; 15: 183-200.
4. Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow up study of the immunogenicity and long term efficacy of plasma derived hepatitis B vaccine in high risk Chinese neonates. Clin Infect Dis 1993; 17: 475-479.
5. Xu ZY, Duan SC, Margolis HS, Purcell RH, Ou-Yang PY, Coleman PJ, et al. Long term efficacy of active postexposure immunogenicity of infants for prevention of hepatitis B virus infection. J Infec Dis 1995; 171: 54-60.
6. Lo KJ, Lee SD, Tsai YT. Combined passive and active immunization for interruption of prenatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology 1985; 8: 1647-1650.
7. Ahn YO. Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. Gut 1996; 38 (Suppl 2): S63-S66.
8. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Prenatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985; 253: 1740.
9. Tong MJ. Hepatitis B vaccination of neonates and children. Am J Med 1989; 87: 33S-35S.
10. Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 2001; 19: 3919-3926.
11. Lolekha S, Warachet B, Hirunyachke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg positive carrier mothers in Thailand. Vaccine 2002; 20: 3739-3743.
12. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261: 3278-3281.
13. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of prenatally transmitted hepatitis B virus infections with immune globulin and hepatitis B vaccine. Lancet 1983; 2: 1099.
14. Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis B vaccine and hepatitis B immunoglobulin. Double-blind randomized placebo-controlled study. Lancet 1984; 1: 921.
15. Vaccination and Immunity Guideline. 5th ed. The Office of Deputy Ministry of Health. Ministry of Health and Medical Education. Tehran (Iran): Seda Publishing; 1998.
16. Sangfeft P, Reichard O, Lidman K, von Sydow M, Forsgren M. Prevention of hepatitis B by immunization of the newborn infant-a long-term follow-up study in Stockholm, Sweden. Scand J Infect Dis 1995; 27: 3-7.
17. Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995; 126 (5 Pt 1): 716-721.
18. Zali MR, Noori Nayer B, Shahraz S, Sherafat R, Mohammad K, Noorbala M et al. Rate of HBsAG positivity in Iran following hepatitis B mass vaccination. J Hepatol 2003; 38 (Suppl 2): 184.
19. Kohn MA, Farley TA, Scott C. The need for more aggressive follow-up of children born to hepatitis B surface antigen-positive mothers: lessons from the Louisiana Prenatal Hepatitis B Immunization Program. Pediatr Infect Dis J 1996; 15: 535-540.
20. Xu ZY, Duan SC, Margolis HS, Purcell RH, Ou-Yang PY, Coleman PJ et al. Long-term efficacy of active post-exposure immunization of infants for prevention of hepatitis B virus infection. J Infec Dis 1995; 171: 54-60.
21. Steven CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292: 771-774.
22. Stevens CE, Tay PT, Tong MJ, Taylor PE, Vyas GN, Nair PV et al. Prevention by passive-active immunization. JAMA 1985; 253: 1740-1745.
23. Amini S, Mahmoodi MF, Andalibi S, Solati AA, Seroepidemiology of hepatitis B, Delta and human immunodeficiency virus infections in Hamadan Province, Iran: a population based study. J Trop Med Hyg 1993; 96: 277-287.
24. Rezvan H. Prevalence of e-antigen and antibody among healthy blood donor carrying hepatitis B surface antigen. Ir J Med Sci 1986; 13: 44-46.
25. Adibi P, Zamani G, Mohammad K, Zali MR. Parents-children transmission of hepatitis B in Iran. J Hepatol 2003; 38 (Suppl 2): 122.
26. Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993; 17: 475-479.
27. Lo KJ, Lee SD, Tsai YT, Wu TC, Chan CY, Chen GH et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg-positive HBsAg-carrier mothers. Hepatology 1988; 8: 1647-1650.
28. Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992; 90: 170-173.
29. Delage G, Rémy-Prince S, Montplaisir S. Combined active-passive immunization against the hepatitis B virus: five-year follow-up of children born to hepatitis B surface antigen positive mothers. Pediatr Infect Dis J 1993; 12: 126-130.
30. Wainwright RB, McMahon BJ, Bulkow LR, Hall DB, Fitzgerald MA, Harpster AP et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989; 261: 2362-2366.
31. Nair S, Perrillo RP. Hepatitis B and D. In: Zakim D, Boyer TD. Hepatology A Textbook of Liver Disease. 4th ed. Philadelphia (PA): Pennsylvania (PA): Saunders; 2003. p. 992.
32. Wu JS, Hwang LY, Goodman KJ, Beasley RP. HHepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999; 179: 1319-1325.
33. Roshan MR, Pasha YZ. Efficacy of HBIG and Vaccination in Infants of HBsAg Positive Carrier Mothers. Archives of Iranian Medicine 2002; 5: 21-23.